AGER and serum lipopolysaccharide activity: Indeed, anti-RAGE antibodies have previously been evaluated in murine models for the treatment of acute sepsis (XT-M4, a monoclonal antibody recognizing the V-domain of RAGE) [42]; halting endotoxemia-related organ disorders (abRAGE recognizing an epitope within the RAGE extracellular domains) [43]; the inhibition of peritoneal fibrosis in diabetic animals (anti-RAGE monoclonal antibody recognizing the RAGE extracellular domains) [44]; and the inhibition of tumor growth in a xenograph melanoma model (anti-RAGE polyclonal antibody recognizing the C1-domain of RAGE) [45].